Related Experiment Video

Updated: Apr 14, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

931

Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma

Ramona Crescenzo1, Francesco Abate2, Elena Lasorsa3

  • 1Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies, University of Torino, 10126 Torino, Italy; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10021, USA.

Cancer Cell
|April 16, 2015
PubMed

Insights

This study comprehensively analyzed genetic alterations in ALK-negative anaplastic large cell lymphoma (ALCL). Key findings reveal JAK/STAT3 pathway mutations and fusions driving ALCL, offering new therapeutic targets.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Anaplastic Large Cell Lymphoma (ALCL) is a heterogeneous non-Hodgkin lymphoma.
  • A comprehensive understanding of the genetic drivers in ALK-negative ALCL (ALK(-) ALCL) is lacking.
  • Identifying these drivers is crucial for developing targeted therapies.

Purpose of the Study:

  • To systematically characterize the genetic alterations, including somatic point mutations, copy number alterations, and gene fusions, in ALK(-) ALCL.
  • To elucidate the role of these alterations in ALK(-) ALCL pathogenesis.
  • To investigate the therapeutic potential of targeting the identified pathways.

Main Methods:

  • Utilized massive sequencing strategies to analyze genetic alterations.
  • Integrated data on somatic point mutations, copy number alterations, and gene fusions.
  • Performed in vitro and in vivo experiments to assess the impact of pathway inhibition.

Main Results:

  • Identified activating mutations in JAK1 and/or STAT3 genes in approximately 20% of ALK(-) ALCL cases.
  • Discovered that 38% of systemic ALK(-) ALCLs exhibited double genetic lesions.
  • Discovered recurrent gene fusions involving transcription factors and tyrosine kinases in ALK(-) ALCL.
  • Demonstrated constitutive activation of the JAK/STAT3 pathway due to these aberrations.
  • Confirmed the oncogenic role of the JAK/STAT3 pathway.

Conclusions:

  • The JAK/STAT3 pathway is a critical oncogenic driver in a significant subset of ALK(-) ALCL.
  • Genetic alterations identified provide novel therapeutic targets for ALK(-) ALCL.
  • Inhibition of the JAK/STAT3 pathway demonstrates anti-cancer effects, supporting its clinical relevance.

More Related Videos

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

15.7K
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

10.1K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.5K